153 related articles for article (PubMed ID: 37660399)
1. Repeatability of quantitative individual lesion and total disease multiparametric whole-body MRI measurements in prostate cancer bone metastases.
Donners R; Candito A; Blackledge M; Rata M; Messiou C; Koh DM; Tunariu N
Br J Radiol; 2023 Nov; 96(1151):20230378. PubMed ID: 37660399
[TBL] [Abstract][Full Text] [Related]
2. Inter- and Intra-Patient Repeatability of Radiomic Features from Multiparametric Whole-Body MRI in Patients with Metastatic Prostate Cancer.
Donners R; Candito A; Rata M; Sharp A; Messiou C; Koh DM; Tunariu N; Blackledge MD
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730599
[TBL] [Abstract][Full Text] [Related]
3. Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing.
Donners R; Figueiredo I; Tunariu N; Blackledge M; Koh DM; de la Maza MLDF; Chandran K; de Bono JS; Fotiadis N
Eur Radiol; 2022 Jul; 32(7):4647-4656. PubMed ID: 35092476
[TBL] [Abstract][Full Text] [Related]
4. Inter- and Intra-Observer Repeatability of Quantitative Whole-Body, Diffusion-Weighted Imaging (WBDWI) in Metastatic Bone Disease.
Blackledge MD; Tunariu N; Orton MR; Padhani AR; Collins DJ; Leach MO; Koh DM
PLoS One; 2016; 11(4):e0153840. PubMed ID: 27123931
[TBL] [Abstract][Full Text] [Related]
5. Multiparametric Magnetic Resonance Imaging of the Prostate: Repeatability of Volume and Apparent Diffusion Coefficient Quantification.
Fedorov A; Vangel MG; Tempany CM; Fennessy FM
Invest Radiol; 2017 Sep; 52(9):538-546. PubMed ID: 28463931
[TBL] [Abstract][Full Text] [Related]
6. Multiparametric bone MRI targeting aides lesion selection for CT-guided sclerotic bone biopsies in metastatic castrate resistant prostate cancer.
Donners R; Figueiredo I; Westaby D; Koh DM; Tunariu N; Carreira S; de Bono JS; Fotiadis N
Cancer Imaging; 2023 Dec; 23(1):121. PubMed ID: 38102655
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric Magnetic Resonance Imaging of Prostate Cancer Bone Disease: Correlation With Bone Biopsy Histological and Molecular Features.
Perez-Lopez R; Nava Rodrigues D; Figueiredo I; Mateo J; Collins DJ; Koh DM; de Bono JS; Tunariu N
Invest Radiol; 2018 Feb; 53(2):96-102. PubMed ID: 28906339
[TBL] [Abstract][Full Text] [Related]
8. Multiparametric Whole-body MRI with Diffusion-weighted Imaging and ADC Mapping for the Identification of Visceral and Osseous Metastases From Solid Tumors.
Jacobs MA; Macura KJ; Zaheer A; Antonarakis ES; Stearns V; Wolff AC; Feiweier T; Kamel IR; Wahl RL; Pan L
Acad Radiol; 2018 Nov; 25(11):1405-1414. PubMed ID: 29627288
[TBL] [Abstract][Full Text] [Related]
9. Comparison of T2-Weighted Imaging, DWI, and Dynamic Contrast-Enhanced MRI for Calculation of Prostate Cancer Index Lesion Volume: Correlation With Whole-Mount Pathology.
Sun C; Chatterjee A; Yousuf A; Antic T; Eggener S; Karczmar GS; Oto A
AJR Am J Roentgenol; 2019 Feb; 212(2):351-356. PubMed ID: 30540213
[TBL] [Abstract][Full Text] [Related]
10. Same-day repeatability and Between-Sequence reproducibility of Mean ADC in PI-RADS lesions.
Zhang KS; Neelsen CJO; Wennmann M; Glemser PA; Hielscher T; Weru V; Görtz M; Schütz V; Stenzinger A; Hohenfellner M; Schlemmer HP; Bonekamp D
Eur J Radiol; 2023 Aug; 165():110898. PubMed ID: 37331287
[TBL] [Abstract][Full Text] [Related]
11. Diffusion-weighted Imaging as a Treatment Response Biomarker for Evaluating Bone Metastases in Prostate Cancer: A Pilot Study.
Perez-Lopez R; Mateo J; Mossop H; Blackledge MD; Collins DJ; Rata M; Morgan VA; Macdonald A; Sandhu S; Lorente D; Rescigno P; Zafeiriou Z; Bianchini D; Porta N; Hall E; Leach MO; de Bono JS; Koh DM; Tunariu N
Radiology; 2017 Apr; 283(1):168-177. PubMed ID: 27875103
[TBL] [Abstract][Full Text] [Related]
12. Noninferiority of Monoparametric MRI Versus Multiparametric MRI for the Detection of Prostate Cancer: Diagnostic Accuracy of ADC Ratios Based on Advanced "Zoomed" Diffusion-Weighted Imaging.
Raczeck P; Frenzel F; Woerner T; Graeber S; Bohle RM; Ziegler G; Buecker A; Schneider GK
Invest Radiol; 2022 Apr; 57(4):233-241. PubMed ID: 34743133
[TBL] [Abstract][Full Text] [Related]
13. Assessment of treatment response by total tumor volume and global apparent diffusion coefficient using diffusion-weighted MRI in patients with metastatic bone disease: a feasibility study.
Blackledge MD; Collins DJ; Tunariu N; Orton MR; Padhani AR; Leach MO; Koh DM
PLoS One; 2014; 9(4):e91779. PubMed ID: 24710083
[TBL] [Abstract][Full Text] [Related]
14. Repeatability and Reproducibility of ADC Measurements and MRI Signal Intensity Measurements of Bone Marrow in Monoclonal Plasma Cell Disorders: A Prospective Bi-institutional Multiscanner, Multiprotocol Study.
Wennmann M; Thierjung H; Bauer F; Weru V; Hielscher T; Grözinger M; Gnirs R; Sauer S; Goldschmidt H; Weinhold N; Bonekamp D; Schlemmer HP; Weber TF; Delorme S; Rotkopf LT
Invest Radiol; 2022 Apr; 57(4):272-281. PubMed ID: 34839306
[TBL] [Abstract][Full Text] [Related]
15. Repeatability of diffusion-weighted MRI of the prostate using whole lesion ADC values, skew and histogram analysis.
Barrett T; Lawrence EM; Priest AN; Warren AY; Gnanapragasam VJ; Gallagher FA; Sala E
Eur J Radiol; 2019 Jan; 110():22-29. PubMed ID: 30599864
[TBL] [Abstract][Full Text] [Related]
16. Repeatability and reproducibility of ADC measurements: a prospective multicenter whole-body-MRI study.
Michoux NF; Ceranka JW; Vandemeulebroucke J; Peeters F; Lu P; Absil J; Triqueneaux P; Liu Y; Collette L; Willekens I; Brussaard C; Debeir O; Hahn S; Raeymaekers H; de Mey J; Metens T; Lecouvet FE
Eur Radiol; 2021 Jul; 31(7):4514-4527. PubMed ID: 33409773
[TBL] [Abstract][Full Text] [Related]
17. Relative fat fraction of malignant bone lesions from breast cancer, prostate cancer and myeloma are significantly lower than normal bone marrow and shows excellent interobserver agreement.
Castagnoli F; Donners R; Tunariu N; Messiou C; Koh DM
Br J Radiol; 2023 Dec; 96(1152):20230240. PubMed ID: 37750943
[TBL] [Abstract][Full Text] [Related]
18. Assessing the relation between bone marrow signal intensity and apparent diffusion coefficient in diffusion-weighted MRI.
Padhani AR; van Ree K; Collins DJ; D'Sa S; Makris A
AJR Am J Roentgenol; 2013 Jan; 200(1):163-70. PubMed ID: 23255758
[TBL] [Abstract][Full Text] [Related]
19. Whole-body MRI including diffusion-weighted imaging (DWI) for patients with recurring prostate cancer: technical feasibility and assessment of lesion conspicuity in DWI.
Eiber M; Holzapfel K; Ganter C; Epple K; Metz S; Geinitz H; Kübler H; Gaa J; Rummeny EJ; Beer AJ
J Magn Reson Imaging; 2011 May; 33(5):1160-70. PubMed ID: 21509875
[TBL] [Abstract][Full Text] [Related]
20. A whole-body diffusion MRI normal atlas: development, evaluation and initial use.
Sjöholm T; Tarai S; Malmberg F; Strand R; Korenyushkin A; Enblad G; Ahlström H; Kullberg J
Cancer Imaging; 2023 Sep; 23(1):87. PubMed ID: 37710346
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
